Search

everythinglearnresearchcommunity

for

Search:↓

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Targeting EGFR may help reduce hair loss from chemotherapy.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.

The CD4 protein may play a role in the behavior of certain skin cells, affecting their growth, movement, and differentiation.

MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

Cepharanthine helps reduce cell aging caused by the cancer drug Doxorubicin by boosting cell cleanup processes.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

A new test helps find drugs to treat head and neck cancer by targeting c-Rel.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Doxycycline can effectively treat hair loss caused by EGFR inhibitors.

Y-27632 helps hair follicle stem cells grow and keep their abilities.

TAF4 is important for skin cell growth and helps prevent skin cancer in mice.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

Coinheritance of BRCA2 and CYLD genes may lead to new treatment options for certain cancers.

A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.

Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.

A mix of specific inhibitors and a growth factor helps keep hair growth cells from losing their properties in the lab.

Patched1 helps prevent tumors by controlling cell growth.

Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.

Upadacitinib successfully treated a child's severe skin and hair loss issues.

MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.

Nilotinib can cause keratosis pilaris, a skin condition.